Sunday, 22 September 2013

Psoriasis drug shows promising results for treating type 1 diabetes




A drug formerly used to treat the skin disorder psoriasis has shown encouraging results in a phase 2 trial to assess its effectiveness in treating type 1 diabetes, according to new research published in The Lancet Diabetes and Endocrinology.


Type 1 diabetes is an autoimmune condition where the body's immune system mistakenly attacks insulin-producing cells in the pancreas, resulting in insulin deficiency and an inability to regulate blood sugar. The condition is thought to affect around 400,000 people in the UK; patients require lifelong treatment with insulin injections, and are at substantially increased risk of illness and death related to their condition.


Trials in the 1980s and 1990s explored the possibility of using immune-supressing drugs to treat , but the risks of long-term immunosuppressant therapy outweighed the benefits. However, in recent years, immune-suppressing drugs have been developed that have a much more specific effect on the that cause problems in autoimmune disorders, while preserving the immune cells which are essential for normal immune functioning.


Alefacept (marketed as Amevive) is one such drug, which has been used for around a decade to successfully treat the skin condition psoriasis (also thought to be an autoimmune disorder, where the immune system attacks healthy ). Results from clinical trials in psoriasis have shown that alefacept works by attacking specific types of T cells (themselves a type of white blood cell) – effector memory (Tem) cells and, to a lesser extent, central memory (Tcm) cells – which are involved in the body's mistaken attack against itself.


Since type 1 diabetes involves Tem cells and Tcm cells attacking insulin-producing cells in the pancreas, a team of researchers led by Professor Mark Rigby of Indiana University and the Riley Hospital for Children in Indianapolis, USA, investigated whether alefacept had any effect on patients newly diagnosed with type 1 diabetes in a study run by the US National Institutes of Health's Immune Tolerance Network.


Between March 2011 and March 2012, 49 individuals from across 14 different clinical centres in the USA were enrolled into the trial, although this was less than the planned 66 participants because alefacept was withdrawn by its manufacturer in December 2011. 33 participants received weekly injections of alefacept for 12 weeks, followed by a break of 12 weeks, and then 12 further weekly doses. 16 participants received a placebo according to the same schedule.


The trial's primary outcome was a measure of how well the pancreas could secrete insulin in response to food, two hours after eating. The researchers found no significant difference between the two groups according to this measure, but there were some notable differences between the groups when the secondary outcomes were analysed. Using the same measure of insulin secretion four hours after eating, there was a significant difference between the study and control group: the group who received alefacept showed preserved insulin secretion, whereas insulin secretion in the placebo group decreased.


Moreover, 12 months after starting treatment, insulin use in the placebo group was significantly higher than in the study group, and those who received alefacept showed no significant increase in insulin use over the course of the trial, whereas those in the placebo group did. These results suggest that treatment with alefacept preserved the body's ability to produce its own insulin. Participants receiving alefacept also had fewer episodes of hypoglycaemia (low blood glucose levels), which are a common and dangerous occurrence in patients requiring insulin shots.


Importantly, alefacept was found to deplete potentially disease-causing Tem cells and Tcm cells while leaving protective regulatory T cells unaffected. Thus, the selective actions of this drug on the immune system might be an improvement over earlier drugs that induced general immune suppression.


According to Professor Rigby, "Alefacept is the first targeted biological drug assessed in patients with new-onset type 1 diabetes that significantly depleted the T cells which attack the pancreas in type 1 diabetes, while preserving other immune cells which are important for pancreatic function. Although the primary endpoint was not met, several key secondary endpoints were significantly different between treatment groups, suggesting that alefacept might preserve pancreas cell function during the first 12 months after diagnosis. Targeting memory T cells might be a useful strategy in type 1 diabetes, but longer follow-up is required to confirm the preliminary signal of efficacy observed at 12 months in the T1DAL trial."


Writing in a linked Comment, Dr Kevan Herold of Yale University, New Haven, USA, says "These new results, together with the findings from recent trials of a CD3 monoclonal antibody, are leading to mechanism-based strategies to restore the balance between those needed for protection against pathogens and those that maintain tolerance to self, rather than broadly eliminating . It is important to underscore these small successes since, as in other fields such as oncology and infectious diseases, the small achievements acquire greater significance when they are combined. In this regard, the withdrawal of pharmaceutical companies from this and other trials, even before the final outcomes of trials were realised, was disappointing—particularly as we move closer to finally reaching the ultimate goal: to prevent, stop, and even reverse type 1 diabetes."



More information: www.thelancet.com/journals/landia/article/PIIS2213-8587(13)70111-6/abstract


Medical Xpress on facebook

Related Stories


T-cell targeted therapy tested in type 1 diabetes study


Aug 27, 2013



Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network (ITN), ...



Drug preserves beta cells in new cases of type 1 diabetes


Aug 06, 2013



(Medical Xpress)—A drug in clinical trials has been shown to preserve insulin-producing pancreatic beta cells in nearly half of subjects newly diagnosed with type 1 diabetes. Results of the phase 2 trials ...



ITN type 1 diabetes study identifies subset of patients with strong response to therapy


Aug 15, 2013



Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, ...



Pancreas stem cell discovery may lead to new diabetes treatments


Nov 14, 2012



(Medical Xpress)—Stem cells in the adult pancreas have been identified that can be turned into insulin producing cells, a finding that means people with type 1 diabetes might one day be able to regenerate ...



Adult stem cells could hold key to curing Type 1 diabetes


May 29, 2013



Millions of people with type 1 diabetes depend on daily insulin injections to survive. They would die without the shots because their immune system attacks the very insulin-producing cells it was designed ...



Recommended for you


Transmitting future asthma by smoking today


Sep 20, 2013



Asthma is a serious public health problem. An estimated 300 million people worldwide suffer from this sometimes deadly lung disease, a number expected to increase to 400 million by 2025. One well-established risk factor for ...



Patient, heal thyself: Solution to personalised treatment for chronic infections could lie in patient's own blood


Sep 20, 2013



A recent discovery by scientists at A*STAR's Singapore Institute for Clinical Sciences (SICS), in close collaboration with researchers at the Singapore Immunology Network (SIgN), provides hope for a new personalised treatment ...



Missing immune response may prove a vital link for new leukaemia treatments


Sep 20, 2013



(Medical Xpress)—Patients suffering from leukaemia could have their immune system engineered to fight the disease, after scientists at the University of Birmingham discovered that they lacked an immune response to a certain ...



Researchers investigating the many ways we get by with a little help from trillions of our bacterial friends


Sep 20, 2013



Everyone's got a personal collection of microbiota. You could think of yours as your unique internal pet—at up to 3 percent of your body mass, it's as hefty as a teacup Yorkie or a large guinea pig—requiring care and ...





Scientists find promising way to boost body's immune surveillance via p53


Sep 18, 2013



Researchers at A*STAR's Singapore Immunology Network (SIgN) have discovered a new mechanism involving p53, the famous tumour suppressor, to fight against aggressive cancers. This strategy works by sabotaging ...





Red grapes, blueberries may enhance immune function


Sep 17, 2013



In an analysis of 446 compounds for their the ability to boost the innate immune system in humans, researchers in the Linus Pauling Institute at Oregon State University discovered just two that stood out ...



User comments








A drug formerly used to treat the skin disorder psoriasis has shown encouraging results in a phase 2 trial to assess its effectiveness in treating type 1 diabetes, according to new research published in The Lancet Diabetes and Endocrinology.


Type 1 diabetes is an autoimmune condition where the body's immune system mistakenly attacks insulin-producing cells in the pancreas, resulting in insulin deficiency and an inability to regulate blood sugar. The condition is thought to affect around 400,000 people in the UK; patients require lifelong treatment with insulin injections, and are at substantially increased risk of illness and death related to their condition.


Trials in the 1980s and 1990s explored the possibility of using immune-supressing drugs to treat , but the risks of long-term immunosuppressant therapy outweighed the benefits. However, in recent years, immune-suppressing drugs have been developed that have a much more specific effect on the that cause problems in autoimmune disorders, while preserving the immune cells which are essential for normal immune functioning.


Alefacept (marketed as Amevive) is one such drug, which has been used for around a decade to successfully treat the skin condition psoriasis (also thought to be an autoimmune disorder, where the immune system attacks healthy ). Results from clinical trials in psoriasis have shown that alefacept works by attacking specific types of T cells (themselves a type of white blood cell) – effector memory (Tem) cells and, to a lesser extent, central memory (Tcm) cells – which are involved in the body's mistaken attack against itself.


Since type 1 diabetes involves Tem cells and Tcm cells attacking insulin-producing cells in the pancreas, a team of researchers led by Professor Mark Rigby of Indiana University and the Riley Hospital for Children in Indianapolis, USA, investigated whether alefacept had any effect on patients newly diagnosed with type 1 diabetes in a study run by the US National Institutes of Health's Immune Tolerance Network.


Between March 2011 and March 2012, 49 individuals from across 14 different clinical centres in the USA were enrolled into the trial, although this was less than the planned 66 participants because alefacept was withdrawn by its manufacturer in December 2011. 33 participants received weekly injections of alefacept for 12 weeks, followed by a break of 12 weeks, and then 12 further weekly doses. 16 participants received a placebo according to the same schedule.


The trial's primary outcome was a measure of how well the pancreas could secrete insulin in response to food, two hours after eating. The researchers found no significant difference between the two groups according to this measure, but there were some notable differences between the groups when the secondary outcomes were analysed. Using the same measure of insulin secretion four hours after eating, there was a significant difference between the study and control group: the group who received alefacept showed preserved insulin secretion, whereas insulin secretion in the placebo group decreased.


Moreover, 12 months after starting treatment, insulin use in the placebo group was significantly higher than in the study group, and those who received alefacept showed no significant increase in insulin use over the course of the trial, whereas those in the placebo group did. These results suggest that treatment with alefacept preserved the body's ability to produce its own insulin. Participants receiving alefacept also had fewer episodes of hypoglycaemia (low blood glucose levels), which are a common and dangerous occurrence in patients requiring insulin shots.


Importantly, alefacept was found to deplete potentially disease-causing Tem cells and Tcm cells while leaving protective regulatory T cells unaffected. Thus, the selective actions of this drug on the immune system might be an improvement over earlier drugs that induced general immune suppression.


According to Professor Rigby, "Alefacept is the first targeted biological drug assessed in patients with new-onset type 1 diabetes that significantly depleted the T cells which attack the pancreas in type 1 diabetes, while preserving other immune cells which are important for pancreatic function. Although the primary endpoint was not met, several key secondary endpoints were significantly different between treatment groups, suggesting that alefacept might preserve pancreas cell function during the first 12 months after diagnosis. Targeting memory T cells might be a useful strategy in type 1 diabetes, but longer follow-up is required to confirm the preliminary signal of efficacy observed at 12 months in the T1DAL trial."


Writing in a linked Comment, Dr Kevan Herold of Yale University, New Haven, USA, says "These new results, together with the findings from recent trials of a CD3 monoclonal antibody, are leading to mechanism-based strategies to restore the balance between those needed for protection against pathogens and those that maintain tolerance to self, rather than broadly eliminating . It is important to underscore these small successes since, as in other fields such as oncology and infectious diseases, the small achievements acquire greater significance when they are combined. In this regard, the withdrawal of pharmaceutical companies from this and other trials, even before the final outcomes of trials were realised, was disappointing—particularly as we move closer to finally reaching the ultimate goal: to prevent, stop, and even reverse type 1 diabetes."



More information: www.thelancet.com/journals/landia/article/PIIS2213-8587(13)70111-6/abstract


Medical Xpress on facebook

Related Stories


T-cell targeted therapy tested in type 1 diabetes study


Aug 27, 2013



Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network (ITN), ...



Drug preserves beta cells in new cases of type 1 diabetes


Aug 06, 2013



(Medical Xpress)—A drug in clinical trials has been shown to preserve insulin-producing pancreatic beta cells in nearly half of subjects newly diagnosed with type 1 diabetes. Results of the phase 2 trials ...



ITN type 1 diabetes study identifies subset of patients with strong response to therapy


Aug 15, 2013



Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, ...



Pancreas stem cell discovery may lead to new diabetes treatments


Nov 14, 2012



(Medical Xpress)—Stem cells in the adult pancreas have been identified that can be turned into insulin producing cells, a finding that means people with type 1 diabetes might one day be able to regenerate ...



Adult stem cells could hold key to curing Type 1 diabetes


May 29, 2013



Millions of people with type 1 diabetes depend on daily insulin injections to survive. They would die without the shots because their immune system attacks the very insulin-producing cells it was designed ...



Recommended for you


Transmitting future asthma by smoking today


Sep 20, 2013



Asthma is a serious public health problem. An estimated 300 million people worldwide suffer from this sometimes deadly lung disease, a number expected to increase to 400 million by 2025. One well-established risk factor for ...



Patient, heal thyself: Solution to personalised treatment for chronic infections could lie in patient's own blood


Sep 20, 2013



A recent discovery by scientists at A*STAR's Singapore Institute for Clinical Sciences (SICS), in close collaboration with researchers at the Singapore Immunology Network (SIgN), provides hope for a new personalised treatment ...



Missing immune response may prove a vital link for new leukaemia treatments


Sep 20, 2013



(Medical Xpress)—Patients suffering from leukaemia could have their immune system engineered to fight the disease, after scientists at the University of Birmingham discovered that they lacked an immune response to a certain ...



Researchers investigating the many ways we get by with a little help from trillions of our bacterial friends


Sep 20, 2013



Everyone's got a personal collection of microbiota. You could think of yours as your unique internal pet—at up to 3 percent of your body mass, it's as hefty as a teacup Yorkie or a large guinea pig—requiring care and ...





Scientists find promising way to boost body's immune surveillance via p53


Sep 18, 2013



Researchers at A*STAR's Singapore Immunology Network (SIgN) have discovered a new mechanism involving p53, the famous tumour suppressor, to fight against aggressive cancers. This strategy works by sabotaging ...





Red grapes, blueberries may enhance immune function


Sep 17, 2013



In an analysis of 446 compounds for their the ability to boost the innate immune system in humans, researchers in the Linus Pauling Institute at Oregon State University discovered just two that stood out ...



User comments








Categories:

0 comments:

Post a Comment